Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

Table 7 Protective efficacy based on mITT by individual study

Study	Treatment	N	# of failures	Median failure time (wk)^a	Person-years	Incidence density^b	PE	95 % CI lower limit	95 % CI upper limit
30	Placebo	93	30	10.1	13.26	226.2
	Tafenoquine 200-mg weekly	99	2	NA	20.96	9.5	95.8	82.3	99
	Mefloquine 250-mg weekly	96	2	NA	17.9	11.2	95.1	79.3	98.8
43	Placebo	60	54	7.0	7.68	703.2
	Tafenoquine 400-mg load only	57	16	NA	11.96	133.7	81	66.8	89.1
	Tafenoquine 200-mg weekly	55	7	NA	12.21	57.3	91.8	82.1	96.3
	Tafenoquine 400-mg weekly	57	6	NA	13.58	44.2	93.7	85.4	97.3
45	Placebo	94	86	4.6	9.65	891.6
	Tafenoquine 25-mg weekly	93	58	7.7	15.32	378.7	57.5	40.7	69.6
	Tafenoquine 50-mg weekly	91	13	NA	20.67	62.9	92.9	87.4	96.1
	Tafenoquine 100-mg weekly	94	11	NA	21.99	50	94.4	89.5	97
	Tafenoquine 200-mg weekly	91	12	NA	21.27	56.4	93.7	88.4	96.5
	Mefloquine 250-mg weekly	46	6	NA	10.77	55.7	93.8	85.7	97.3

CI confidence interval, mITT modified intent-to-treat, N number of subjects, PE protective efficacy
^aMedian time for treatment groups with small number of events cannot be estimated due to the sparseness of the data
^bIncidence density rate is expressed in terms of number of prophylactic failures per 100 person-years

ISSN: 1475-2875